Goldline Pharmaceutical IPO Day 3 Subscription Status Stood At 840X

goldline-pharmaceutical-ipo-subscription

You can set Kotak Neo as a preferred source to receive regular market updates.

Add as preferred source on Google

The subscription status of Goldline Pharmaceutical IPO stood at 840.74 times on day 3, with strong participation from NIIs and retail investors.

Goldline Pharmaceutical’s initial public offering (IPO) was subscribed 840.74 times on day 3 (14 May 2026). Through its initial public offering, Goldline Pharmaceutical seeks to raise ₹11.61 crore. Today was the last day of bidding for this IPO, which opened for subscription on 12 May.

Check Goldline Pharmaceutical Allotment Status

Just like the first two days of bidding, the IPO saw strong participation from non-institutional investors (NIIs) and retail investors today. However, the response from qualified institutional bidders (QIBs) was a little muted.

The table highlights the subscription status of various categories of investors for the Goldline Pharmaceutical IPO on day 3:

The table below highlights the day-wise subscription status of the Goldline Pharmaceutical IPO:

The table highlights the key details of this IPO:

Goldline Pharmaceutical is engaged in the marketing of pharma products under the ‘Goldline’ brand name. The company’s products are organised into five segments, namely:

  • Goldline Pharma

  • Goldline Cardinal

  • Goldline Aayushman

  • Goldline InLife

  • Goldline Wellness

Also Read - Post-Market, 14 May 2026: Sensex Zooms Past 75,350; Nifty Gains 1.18%

The company plans to use the IPO proceeds for repaying certain outstanding borrowings and general corporate purposes.

Sources:

Chittorgarh

RHP

This article is for informational purposes only and should not be considered investment advice from Kotak Neo. For compliance T&C and disclaimers, Visit https://www.kotakneo.com/disclaimer/

About the Author
Kotak News Desk
Kotak News Desk

Kotak News Desk brings you latest updates, expert insights, and market-ready ideas - helping you stay informed and invest smarter.

Connect on: Linkedin

Did you enjoy this article?

0 people liked this article.